Any given tumor is composed of a multitude of cell types that can each look or behave differently from its neighbors. An emerging body of research suggests that these differences can influence disease progression or the way ...
Nov 18, 2020
0
69
Scientists have created a three-dimensional (3-D) tumor model in the laboratory for ovarian cancer that could lead to improved understanding and treatment of the disease.
Oct 2, 2020
0
84
An aggressive form of the childhood cancer neuroblastoma could be treatable with two cancer drugs currently used in the treatment of colon and ovarian cancer, a study led by researchers at The Institute of Cancer Research, ...
Sep 29, 2020
0
4
After nearly four years of work, a group of researchers and clinicians from the University of Colorado (CU) published a paper this week in the Clinical Cancer Research that shares findings from research looking at how the ...
Sep 15, 2020
0
9
With advances in genome sequencing, cancer treatments have increasingly sought to leverage the idea of "synthetic lethality," exploiting cancer-specific genetic defects to identify targets that are uniquely essential to the ...
Jul 27, 2020
0
186
A type of drug known as a PARP inhibitor, already used to treat breast and ovarian cancer, may be useful in treating children with high-risk neuroblastoma—a common childhood tumor with a low survival rate.
Jun 25, 2020
0
6
High-grade serous ovarian cancer is the most common type of ovarian cancer, and has the lowest rate of survival. It is often only diagnosed when it has already spread within the pelvis and abdomen, making it harder to treat. ...
May 27, 2020
0
39
Around 1500 Australian women will be diagnosed with ovarian cancer this year, and one woman will die every eight hours from this disease.
May 26, 2020
0
142
The rogue cellular engine that drives a majority of ovarian cancers remains frustratingly difficult to disable. A new study comparing cancerous tissue with normal fallopian tube samples advances important insights about this ...
May 19, 2020
0
23
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.
Apr 28, 2020
0
178
